Amantadine Inhibits SARS-CoV-2 In Vitro

Viruses

Karl-Heinz Eisele¹  Klaus Fink¹  Wojciech Danysz¹  Andreas Nitsche²  Markus Neumann²  Marica Grossegesse² 

[1] Merz Pharmaceuticals GmbH, 60318 Frankfurt, Germany;Robert-Koch-Institut, Zentrum für Biologische Gefahren und Spezielle Pathogene: Hochpathogene Viren (ZBS 1), 13353 Berlin, Germany;

关键词: amantadine;    antiviral drugs;    Covid-19;    SARS-CoV-2;   

DOI  :  10.3390/v13040539

来源: DOAJ

【 摘 要 】

Since the SARS-CoV-2 pandemic started in late 2019, the search for protective vaccines and for drug treatments has become mandatory to fight the global health emergency. Travel restrictions, social distancing, and face masks are suitable counter measures, but may not bring the pandemic under control because people will inadvertently or at a certain degree of restriction severity or duration become incompliant with the regulations. Even if vaccines are approved, the need for antiviral agents against SARS-CoV-2 will persist. However, unequivocal evidence for efficacy against SARS-CoV-2 has not been demonstrated for any of the repurposed antiviral drugs so far. Amantadine was approved as an antiviral drug against influenza A, and antiviral activity against SARS-CoV-2 has been reasoned by analogy but without data. We tested the efficacy of amantadine in vitro in Vero E6 cells infected with SARS-CoV-2. Indeed, amantadine inhibited SARS-CoV-2 replication in two separate experiments with IC₅₀ concentrations between 83 and 119 µM. Although these IC₅₀ concentrations are above therapeutic amantadine levels after systemic administration, topical administration by inhalation or intranasal instillation may result in sufficient amantadine concentration in the airway epithelium without high systemic exposure. However, further studies in other models are needed to prove this hypothesis.

【 授权许可】

Unknown